Browse the newest complete recall records currently stored from FDA enforcement reports and NHTSA vehicle campaigns. “Latest” refers to the newest source-dated record in this database, not the timestamp of our last API check.
The newest recall records with useful source details are listed here.
Out of Specification for active ingredient. Violative grade of propylene glycol used during the manufacturing process.
Labeling: Label Mix-up - product labeled as tirzepatide contains testosterone cypionate
Out of Specification for active ingredient. Violative grade of propylene glycol used during the manufacturing process.
Out of Specification for active ingredient. Violative grade of propylene glycol used during the manufacturing process.
Defective container: lack of seal integrity.
Lack of Assurance of Sterility
Out of Specification for active ingredient. Violative grade of propylene glycol used during the manufacturing process.
Out of Specification for active ingredient. Violative grade of propylene glycol used during the manufacturing process.
Lack of Assurance of Sterility: Complaints of syringe breakage
Ford Motor Company (Ford) is recalling certain 2024 Mustang vehicles. The clutch pressure line may be improperly secured and contact hot exhaust components, which can result in melting of…
Honda (America Honda Motor Co.) is recalling certain 2018-2020 Fit and 2019-2022 HR-V vehicles that were previously recalled under NHTSA recall number 23V-046. The rearview camera image may…
Lack of Assurance of Sterility.
Presence of Foreign Substance: This oil based product may contain trace amounts of water for injection (WFI).
Tesla, Inc. (Tesla) is recalling certain 2012-2024 Model S, 2015-2024 Model X, 2017-2023 Model 3, and 2020-2023 Model Y vehicles. In the event of an unbelted driver, the seat belt warning…
Presence of foreign substance: Product complaint of foreign material in reconstituted bottle.
Microbial Contamination of Non-Sterile Products - Presence of Acetobacter nitrogenifigens bacteria
Presence of Particulate Matter: Potential for black particulates in the drug product.
Presence of foreign substance: Product complaint of foreign material in reconstituted bottle.
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Discoloration: Dotted and yellow spots on tablets
Presence of Foreign Tablets: Pharmacist reported a tablet of baclofen in a bottle of 1000-count tramadol
Presence of Foreign Tablets: Manufacturer received a report from a Pharmacist who reported finding a tablet of baclofen in a bottle of 1000-count tramadol
Browse recent months with enough recall history for useful comparison.
